Clinical Trial: A Phase 1b Study to Evaluate the PK of CSL300 (Clazakizumab) in Chinese Subjects With End Stage Kidney Disease (ESKD)

U.S., June 3 -- ClinicalTrials.gov registry received information related to the study (NCT07619820) titled 'A Phase 1b Study to Evaluate the PK of CSL300 (Clazakizumab) in Chinese Subjects With End Stage Kidney Disease (ESKD)' on May 26.

Brief Summary: This is a phase 1b, partial-blind (Sponsor unblinded), randomized, multicenter, placebo-controlled study. The primary objective of this study is to evaluate the pharmacokinetics (PK) of CSL300 after single and multiple doses in Chinese participants with end stage kidney disease (ESKD) undergoing dialysis.

Study Start Date: June 30

Study Type: INTERVENTIONAL

Condition: End Stage Kidney Disease (ESKD)

Intervention: BIOLOGICAL: CSL300

CSL300 is a humanized anti-interleukin 6 (anti-IL-6) ...